Alpha-1 Antitrypsin Deficiency

Chronic obstructive pulmonary disease or COPD for short is a lung disease that affects millions of people each year. COPD is a general term used to describe diseases such as emphysema and chronic bronchitis. In emphysema there is damage to the walls of the air sacs (alveoli) in the lungs. The earliest symptom of emphysema is shortness of breath during activity. Later the shortness of breath can occur at rest also.

What can cause emphysema?
Most cases of emphysema are caused by smoking or other environmental factors. There is growing evidence that genetics can also increase the risk of developing emphysema. In about one out of every 50 cases of emphysema, there is a specific hereditary basis for developing disease at an earlier age. This results in worse disease than normally seen with the risk factors for developing disease. Sometimes there are no obvious risk factors for developing disease, yet disease is present.

The inherited form of emphysema is called Alpha-1 Antitrypsin Deficiency or "Alpha-1" for short. People with this disorder don’t have enough of a major protein in the blood. This protein is Alpha-1 antitrypsin. Although there are many different genetic variations of this protein, only some will cause lung disease. The most common variant of the protein is often seen in people of northern European descent, especially Scandinavians. Recent evidence shows that Alpha-1 can be found in all populations and all ethnic groups.

What does the Alpha-1 antitrypsin protein do in the body?
Alpha-1 antitrypsin is a major protein in the blood. It is produced mainly in the liver cells and goes into the blood stream to protect against inflammation. It protects the lung by blocking the effects of powerful enzymes called elastase. Elastase is normally carried in white blood cells and protects the delicate tissue of the lung by killing bacteria and neutralizing tiny particles inhaled into the lung.

Alpha-1 antitrypsin inactivates elastase once it has finished its job. Without alpha-1 antitrypsin, elastase can destroy the air sacs of the lung.

How is the diagnosis made?
Because Alpha-1 related disease is COPD, the diagnosis is made by the same methods. Your
doctor may have you do a number of tests to evaluate your breathing. These may include:
- Detailed medical history including family history of lung disease,
- Physical exam,
- Breathing tests and X-rays and
- Oxygen levels.

Two special blood tests determine the diagnosis of Alpha-1 Antitrypsin Deficiency. The first test measures the concentration of Alpha-1 antitrypsin in the blood. A second blood test determines the actual gene product in the person with the disease. The normal gene is an MM genetic pattern. This leads to normal levels of Alpha-1 antitrypsin in the blood. The most common abnormal genetic pattern seen with Alpha-1 is ZZ. Some people may inherit only a single abnormal gene, such as MZ. The normal population that smokers have a 20 percent chance of developing emphysema and with the MZ genetic pattern the risk of emphysema is now 50 percent.

**How is Alpha-1 Antitrypsin Deficiency managed?**

Specific therapy has been available for Alpha-1 related emphysema since 1987; a class of medicine called augmentation therapy. This medicine increases the Alpha-1 protein in the blood with normal Alpha-1 antitrypsin from healthy plasma donors. It is given in a vein (IV). The dose is adjusted based on body weight. This treatment is often given once a week. There are several brands of augmentation therapy (alpha proteinase inhibitors). They include:
- Aralast NP
- Glassia
- Prolastin®C
- Zemaira®

In addition to medicines, the management of Alpha-1 related emphysema includes:
- Exercise and a healthy lifestyle including giving up smoking,
- Avoidance of infection,
- Medication therapy,
- Oxygen therapy,
- Breathing retraining,
- Techniques to bring up mucus and
- Pulmonary rehabilitation.

Giving up smoking and avoiding secondhand smoke are both very important. Smoking will accelerate or speed the development of the disease and shorten the lifespan. Ask your health care provider about techniques to help you give up smoking.

Genetic counseling is important for family members of the person diagnosed with Alpha-1 related emphysema. Family planning issues and early interventions, such as giving up smoking can be addressed.

Lung transplants or lung reduction surgery may be an option for people severely affected by the disorder.

It is important to appreciate that people with Alpha-1 may never develop emphysema. That is why Alpha-1 is referred to as a disorder or condition, rather than a disease. People with Alpha-1 are also at risk of developing liver disease and certain skin conditions. There may also be an association between Alpha-1 NTM infections in the lung, also called non-tuberculous mycobacteria.

Note: This information is provided as an educational service of National Jewish. It is not meant to be a substitute for consulting with your own physician.

PTE.024
The Mount Sinai – National Jewish Health Respiratory Institute was formed by the Icahn School of Medicine at Mount Sinai, a top ranked academic medical center in New York City, and National Jewish Health, the nation’s leading respiratory hospital, based in Denver, Colorado. Combining the strengths of both organizations into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. The Respiratory Institute is based in New York City on the campus of Mount Sinai.